Paper Details

  1. Home
  2. Paper Details

Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma.

Author: BuchbinderDavid, DeripapaElena, DorseyMorna J, EloitMarc, HauckFabian, HautalaTimo, IcenogleJoseph, MoshousDespina, PerelyginaLudmila, SullivanKathleen E, UriarteIgnacio

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The drug nitazoxanide has shown in vitro effectiveness against the rubella virus. This study aims to assess the in vivo effectiveness of nitazoxanide therapy in patients with immunodeficiency-related vaccine-derived rubella.
Paper Details　
Original Abstract of the Article :
Nitazoxanide was recently reported as having in vitro effectiveness against the rubella virus. Immunodeficiency-related vaccine-derived rubella occurs in some patients who have an inherited immunodeficiency and who received the MMR vaccine. This study investigated the in vivo effectiveness of nitazo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/30680653

データ提供：米国国立医学図書館（NLM）

Nitazoxanide: A Potential Treatment for Rubella Virus-Associated Granuloma

Imagine a camel caravan, traversing a sandy desert, encountering a rare and potentially dangerous oasis. Rubella virus-associated granuloma is a rare complication that can occur in patients with immunodeficiency, often after receiving the MMR vaccine. This study investigates the effectiveness of nitazoxanide, a medication, in treating this condition. The researchers explore the in vivo efficacy of nitazoxanide in a case series of patients with primary immunodeficiencies and rubella virus-associated granuloma, offering hope for a treatment option for this challenging condition.

Nitazoxanide's Effectiveness in Treating Rubella Virus-Associated Granuloma

The study provides promising results for the use of nitazoxanide in treating rubella virus-associated granuloma in patients with primary immunodeficiencies. It highlights the potential of this medication as a treatment option for this rare and challenging condition.

Hope for Patients with Immunodeficiencies

This research provides hope for patients with primary immunodeficiencies who develop rubella virus-associated granuloma. It underscores the need for further research to confirm the effectiveness of nitazoxanide and explore its potential benefits for other complications related to immunodeficiency.

Dr.Camel's Conclusion

This study suggests that nitazoxanide may be an effective treatment option for rubella virus-associated granuloma in patients with primary immunodeficiencies. Further research is needed to confirm its efficacy and explore its potential benefits for other complications related to immunodeficiency.

Date :
  1. Date Completed 2019-11-26
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

30680653

DOI: Digital Object Identifier

NIHMS1519538

Related Literature

Article Analysis
・Effective treatment of rubella
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.